Alnylam Says European Patent Office Issues
Patent On RNAi Technology Licensed by Company
Alnylam Pharmaceuticals said this week that the European Patent Office has issued a patent on technology, to which the company holds an exclusive license, related to the therapeutic use of double-stranded RNA expressed from endogenous templates or expression vectors to mediate RNA interference.
Alnylam said that it holds the rights to the patent under an agreement with Cancer Research Technology Limited.